US2021087217A1PendingUtilityA1
Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus
Est. expiryFeb 1, 2037(~10.5 yrs left)· nominal 20-yr term from priority
C07H 1/00C07H 19/20A61K 31/7076C07H 19/207A61P 31/14C07B 2200/13A61K 31/708A61K 9/2054A61K 9/20A61K 45/06
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of the formula:
2 . The compound of claim 1 of the formula:
3 . The compound of claim 2 wherein the compound is at least 90% free of the opposite phosphorus S-enantiomer.
4 . The compound of claim 3 wherein the compound is at least 98% free of the opposite phosphorus S-enantiomer.
5 . The compound of claim 1 of the formula:
6 . The compound of claim 5 wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.
7 . The compound of claim 6 wherein the compound is at least 98% free of the opposite phosphorus R-enantiomer.
8 . A pharmaceutical composition comprising a compound of the formula:
in a pharmaceutically acceptable carrier.
9 . The pharmaceutical composition of claim 8 , comprising a compound of the formula:
in a pharmaceutically acceptable carrier.
10 . The pharmaceutical composition of claim 9 , wherein the compound is at least 90% free of the opposite phosphorus S-enantiomer.
11 . The pharmaceutical composition of claim 10 , wherein the compound is at least 98% free of the opposite phosphorus S-enantiomer.
12 . The pharmaceutical composition of claim 8 , comprising a compound of the formula:
in a pharmaceutically acceptable carrier.
13 . The pharmaceutical composition of claim 12 , wherein the compound is at least 90% free of the opposite phosphorus R-enantiomer.
14 . The pharmaceutical composition of claim 13 , wherein the compound is at least 98% free of the opposite phosphorus R-enantiomer.
15 . The pharmaceutical composition of claim 8 , wherein the pharmaceutically acceptable carrier is suitable for oral delivery.
16 . The pharmaceutical composition of claim 15 , wherein the pharmaceutically acceptable dosage form suitable for oral delivery is in a solid dosage form.
17 . The pharmaceutical composition of claim 16 , wherein the pharmaceutically acceptable carrier is in the form of a tablet or a capsule.
18 . The pharmaceutical composition of claim 15 , wherein the pharmaceutically acceptable dosage form suitable for oral delivery is in a liquid dosage form.
19 . The pharmaceutical composition of claim 18 , wherein the pharmaceutically acceptable carrier is in the form of a suspension or solution.
20 . The pharmaceutical composition of claim 15 , in an intravenous formulation.
21 . The pharmaceutical composition of claim 15 , in a parenteral formulation.
22 . A method to treat hepatitis C in a human in need thereof comprising an effective amount of a compound of the formula:
optionally in a pharmaceutically acceptable carrier.
23 . The method of claim 22 comprising a compound of the formula:
optionally in a pharmaceutically acceptable carrier.
24 . The method of claim 22 comprising a compound of the formula:
optionally in a pharmaceutically acceptable carrier.Join the waitlist — get patent alerts
Track US2021087217A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.